LHLouise Aas Holm

Louise Aas Holm

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Louise Aas Holm has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of modifiable plasma protein markers of cardiometabolic risk in children and adolescents with obesity

    by Sara Elizabeth Stinson, Yun Huang, Roman Thielemann, Evelina Stankevic, Morten Asp Vonsild Lund, Louise Aas Holm, Cilius Esmann Fonvig, Helene Bæk Juel, Dmitrii Borisevich, Maja Thiele, et al.

    Pediatric obesity is linked to multi-organ inflammation and an increased risk of cardiometabolic and steatotic liver disease. To identify circulating biomarkers of cardiometabolic risk, we performed proximity extension assay proteomics, to quantify 149 inflammation- and cardiovascular-related proteins in a cross-sectional study of 4024 children and adolescents (2377 with obesity and 1647 with normal weight). We identified protein signatures linked to obesity, dyslipidemia, insulin resistance, hyperglycemia, hypertension, and related cardiometabolic phenotypes. Using machine learning, a three-protein panel (CDCP1, FGF21, HAOX1) combined with liver enzymes improved prediction of steatotic liver disease versus liver enzymes alone (receiver operating characteristic–area under the curve (ROC–AUC) = 0.83 vs. 0.77; DeLong’s test, P < 0.05). During a 1-year non-pharmacological obesity intervention (n = 184), reductions in adiposity were associated with decreased inflammatory cytokines (including CDCP1, FGF21), which correlated with improvements in cardiometabolic risk profiles. Here we show that circulating proteomic signatures may mediate obesity-related cardiometabolic risk in youth.


  • Open Access

    Genetic subtyping of obesity reveals biological insights into the uncoupling of adiposity from its cardiometabolic comorbidities

    by Nathalie Chami, Zhe Wang, Victor Svenstrup, Virginia Diez Obrero, Daiane Hemerich, Yi Huang, Hesam Dashti, Eleonora Manitta, Michael H. Preuss, Kari E. North, et al.

    Obesity is a heterogeneous condition not adequately captured by a single adiposity trait. We conducted a multi-trait genome-wide association analysis using individual-level data from 452,768 UK Biobank participants to study obesity in relation to cardiometabolic health. We defined continuous ‘uncoupling phenotypes’, ranging from high adiposity with healthy cardiometabolic profiles to low adiposity with unhealthy ones. We identified 266 variants across 205 genomic loci where adiposity-increasing alleles were simultaneously associated with lower cardiometabolic risk. A genetic risk score (GRSuncoupling) aggregating these variants was associated with a lower risk of cardiometabolic disorders, including dyslipidemia and ischemic heart disease, despite higher obesity risk; unlike an adiposity score based on body fat percentage-associated variants (GRSBFP). The 266 variants formed eight genetic subtypes of obesity, each with distinct risk profiles and pathway signatures. Proteomic analyses revealed signatures separating adiposity- and health-driven effects. Our findings reveal new mechanisms that uncouple obesity from cardiometabolic comorbidities and lay a foundation for genetically informed subtyping of obesity to support precision medicine.


  • Open Access

    Identification of modifiable plasma protein markers of cardiometabolic risk in children and adolescents with obesity

    by Sara Elizabeth Stinson, Yun Huang, Roman Thielemann, Evelina Stankevic, Morten Asp Vonsild Lund, Louise Aas Holm, Cilius Esmann Fonvig, Helene Bæk Juel, Dmitrii Borisevich, Maja Thiele, et al.

    Pediatric obesity is associated with multi-organ inflammation and an increased risk of cardiometabolic disease. To identify novel biomarkers of early-onset obesity-related cardiometabolic risk, we performed targeted proteomics, analyzing 149 proteins related to inflammation and cardiovascular disease in a cross-sectional sample of 2,377 children and adolescents with overweight/obesity and 1,647 with normal weight. In addition, we analyzed 64 circulating inflammation-related proteins in 184 children and adolescents, who participated in a 1-year family-based obesity management program. We identified a three plasma protein panel (CDCP1, FGF21 and HAOX1) that improved prediction of hepatic steatosis, compared with the predictive value of liver enzymes alone. In the prospective trial, we found that the non-pharmacological intervention induced a decline in circulating inflammatory cytokine levels, some of which were linked to improvements in cardiometabolic phenotypes. Our results may suggest that circulating proteomic signatures may mediate the associations between pediatric obesity and cardiometabolic risk.


  • Top Cited Papers
    Open Access

    Plasma proteome variation and its genetic determinants in children and adolescents

    by Lili Niu, Sara Elizabeth Stinson, Louise Aas Holm, Morten Asp Vonsild Lund, Cilius Esmann Fonvig, Leonardo Cobuccio, Jonas Meisner, Helene Bæk Juel, Joao Fadista, Maja Thiele, et al.

    Our current understanding of the determinants of plasma proteome variation during pediatric development remains incomplete. Here, we show that genetic variants, age, sex and body mass index significantly influence this variation. Using a streamlined and highly quantitative mass spectrometry-based proteomics workflow, we analyzed plasma from 2,147 children and adolescents, identifying 1,216 proteins after quality control. Notably, the levels of 70% of these were associated with at least one of the aforementioned factors, with protein levels also being predictive. Quantitative trait loci (QTLs) regulated at least one-third of the proteins; between a few percent and up to 30-fold. Together with excellent replication in an additional 1,000 children and 558 adults, this reveals substantial genetic effects on plasma protein levels, persisting from childhood into adulthood. Through Mendelian randomization and colocalization analyses, we identified 41 causal genes for 33 cardiometabolic traits, emphasizing the value of protein QTLs in drug target identification and disease understanding.


  • Open Access

    Protocol for a randomised, double-blinded, controlled trial of youth with childhood-onset obesity treated with semaglutide 2.4 mg/week: the RESETTLE trial

    by Sarah Byberg, Joachim Holt, Rasmus Michael Sandsdal, Louise Aas Holm, Lærke Bruun Madsen, Bodil Just Christensen, Simon Birk Kjær Jensen, Torben Hansen, Jens-Christian Holm, Signe Torekov

    Introduction: Childhood-onset obesity poses significant health risks, including early-onset type 2 diabetes, cardiovascular disease, and reduced quality of life. Hospital-based non-pharmacological obesity care can reduce childhood obesity, but 25% of children do not respond. Therefore, this study investigates the effect of the glucagon-like peptide-1 receptor agonist, semaglutide, as an add-on to hospital-based obesity care in youth who still have obesity following hospital-based obesity care as children. Furthermore, biomedical and psychosocial factors linked to treatment response will be investigated, alongside an exercise-based strategy to prevent weight regain and maintain a healthy body composition after semaglutide treatment. Methods and analysis: This is an investigator-initiated, randomised, placebo-controlled, double-blind trial. We will enrol expectedly 180–270 young adults aged 18–28 years based on their previous response to a paediatric obesity management programme and their current body mass index (BMI). Participants are categorised into four groups: low treatment response (BMI SD score (SDS) reduction 0.25; BMI ≥30 kg/m 2 ); high treatment response (BMI SDS reduction >0.50; BMI 2 ) and a population-based reference group with normal weight development in childhood. Participants with BMI ≥30 kg/m 2 are randomised 2:1 to subcutaneous injections of semaglutide 2.4 mg/week or placebo as an add-on to hospital-based obesity care for 68 weeks. The primary outcome is the change in BMI from randomisation to the end of treatment with semaglutide compared with placebo. Secondary endpoints are changes in weight and body composition. Ethics and dissemination: The trial has been approved by the Danish Medicines Agency and the Ethical Committee of the Capital Region of Denmark (H-20039422). The trial will be conducted in accordance with the Declaration of Helsinki and follow the guidelines for Good Clinical Practice. Results will be presented at international scientific conferences and published in peer-reviewed scientific journals. Trial registration number: EudraCT 2019-002274-31.


  • Assessing prediabetes and cardiometabolic risk in Danish youth with obesity

    by Anna Katrine Gaul, Louise Aas Holm, Torben Hansen, Jens-Christian Holm, Cilius Esmann Fonvig

    Objectives: To investigate how four different prediabetes definitions (by fasting plasma glucose (FPG), glycosylated haemoglobin (HbA1c), FPG-or-HbA1c, or FPG-and-HbA1c) affect prediabetes prevalence estimates and their association with cardiometabolic risk in Danish children and adolescents referred for tertiary obesity treatment. Methods: This cross-sectional study included 5–18-year-olds with BMI SDS above 1.28 and blood samples taken within 30 days of obesity treatment initiation. Anthropometric measurements, blood pressure, and blood samples were analysed to determine prediabetes prevalence and calculate odds ratios for hypertension, dyslipidaemia, abdominal obesity, high alanine aminotransferase (ALT), and BMI SDS ≥99th percentile. Results: Among 2,849 children and adolescents, prediabetes prevalence was 12.8 %, 6.6 %, 17.2 %, and 2.2 % when applying the FPG, HbA1c, FPG-or-HbA1c, and FPG-and-HbA1c definitions, respectively. Hypertension, dyslipidaemia, abdominal obesity, high ALT, and BMI SDS ≥99th percentile phenotypes were common, with increased prevalence among individuals with prediabetes defined from FPG-or-HbA1c. The FPG-derived definition of prediabetes was associated with hypertension and abdominal obesity, while the HbA1c-derived definition of prediabetes was associated with dyslipidaemia, high ALT, and BMI SDS ≥99th percentile. The strongest association was between the FPG-derived definition and hypertension. Conclusions: The FPG-derived definition identified more individuals with prediabetes than the HbA1c-derived definition. Children and adolescents with prediabetes defined from FPG-or-HbA1c exhibited a high burden of hypertension, dyslipidaemia, abdominal obesity, high ALT, and BMI SDS ≥99th percentile. No single diagnostic test proved superior, as each associated with different cardiometabolic risk factors.


  • High Plasma Levels of Soluble Lectin‐like Oxidized Low‐Density Lipoprotein Receptor‐1 Are Associated With Inflammation and Cardiometabolic Risk Profiles in Pediatric Overweight and Obesity

    by Sara E. Stinson, Anna E. Jonsson, Mette K. Andersen, Morten A. V. Lund, Louise Aas Holm, Cilius E. Fonvig, Yun Huang, Evelina Stankevič, Helene Bæk Juel, Lars Ängquist, et al.

    Background: Lectin‐like oxidized low‐density lipoprotein (ox‐LDL) receptor‐1 is a scavenger receptor for oxidized low‐density lipoprotein. In adults, higher soluble lectin‐like ox‐LDL receptor‐1 (sLOX‐1) levels are associated with cardiovascular disease, type 2 diabetes, and obesity, but a similar link in pediatric overweight/obesity remains uncertain. Methods and Results: Analyses were based on the cross‐sectional HOLBAEK Study, including 4‐ to 19‐year‐olds from an obesity clinic group with body mass index >90th percentile (n=1815) and from a population‐based group (n=2039). Fasting plasma levels of sLOX‐1 and inflammatory markers were quantified, cardiometabolic risk profiles were assessed, and linear and logistic regression analyses were performed. Pubertal/postpubertal children and adolescents from the obesity clinic group exhibited higher sLOX‐1 levels compared with the population ( P P P =4.1 E‐04), insulin resistance (OR, 1.16, P =8.6 E‐04), dyslipidemia (OR, 1.25, P =1.8 E‐07), and hypertension (OR, 1.12, P =0.02). Conclusions: sLOX‐1 levels were elevated during and after puberty in children and adolescents with overweight/obesity compared with population‐based peers and associated with inflammatory markers and worsened cardiometabolic risk profiles. sLOX‐1 may serve as an early marker of cardiometabolic risk and inflammation in pediatric overweight/obesity. Registration: The HOLBAEK Study, formerly known as The Danish Childhood Obesity Biobank, ClinicalTrials.gov identifier number NCT00928473, https://clinicaltrials.gov/ct2/show/NCT00928473 (registered June 2009).


  • Open Access

    Possible prediction of obesity‐related liver disease in children and adolescents using indices of body composition

    by Magnus Jung Johansen, Morten Asp Vonsild Lund, Lars Ängquist, Cilius Esmann Fonvig, Louise Aas Holm, Elizaveta Chabanova, Henrik S. Thomsen, Torben Hansen, Jens‐Christian Holm

    Summary: Background: Diagnosis of nonalcoholic fatty liver disease in children and adolescents currently requires advanced or invasive technologies.Objectives: We aimed to develop a method to improve diagnosis, using body composition indices and liver biochemical markers.Methods: To diagnose non‐alcoholic fatty liver disease, 767 Danish children and adolescents underwent clinical examination, blood sampling, whole‐body dual‐energy X‐ray absorptiometry scanning and proton magnetic resonance spectroscopy for liver fat quantification. Fourteen variables were selected as a starting point to construct models, narrowed by stepwise selection. Individuals were split into a training set for model construction and a validation test set. The final models were applied to 2120 Danish children and adolescents to estimate the prevalence.Results: The final models included five variables in different combinations: body mass index–standard deviation score, android‐to‐gynoid‐fat ratio, android‐regional fat percent, trunk‐regional fat percent and alanine transaminase. When validated, the sensitivity and specificity ranged from 38.6% to 51.7% and 87.6% to 91.9%, respectively. The estimated prevalence was 24.2%–35.3%. Models including alanine transaminase alongside body composition measurements displayed higher sensitivity.Conclusions: Body composition indices and alanine transaminase can be used to estimate non‐alcoholic fatty liver disease, with 38.6%–51.7% sensitivity and 87.6%–91.9%, specificity, in children and adolescents with overweight (including obesity). These estimated a 24.2%–35.3% prevalence in 2120 patients.


  • Quality of life in children and adolescents with overweight or obesity: Impact of obstructive sleep apnea

    by Kathrine Nordblad Fenger, Ida Gillberg Andersen, Louise Aas Holm, Jens-Christian Holm, Preben Homøe


  • Open Access

    Impaired glucose metabolism and altered gut microbiome despite calorie restriction of ob/ob mice

    by Alireza Kashani, Asker Daniel Brejnrod, Chunyu Jin, Timo Kern, Andreas Nygaard Madsen, Louise Aas Holm, Georg K. Gerber, Jens-Christian Holm, Torben Hansen, Birgitte Holst, et al.

    Growing evidence supports the role of gut microbiota in obesity and its related disorders including type 2 diabetes. Ob/ob mice, which are hyperphagic due to leptin deficiency, are commonly used models of obesity and were instrumental in suggesting links between gut microbiota and obesity. Specific changes in their gut microbiota such as decreased microbial diversity and increased Firmicutes to Bacteroidetes ratio have been suggested to contribute to obesity via increased microbiota capacity to harvest energy. However, the differential development of ob/ob mouse gut microbiota compared to wild type microbiota and the role of hyperphagia in their metabolic impairment have not been investigated thoroughly. We performed a 10-week long study in ob/ob (n = 12) and wild type control (n = 12) mice fed ad libitum. To differentiate effects of leptin deficiency from hyperphagia, we pair-fed an additional group of ob/ob mice (n = 11) based on the food consumption of control mice. Compared to control mice, ob/ob mice fed ad libitum exhibited compromised glucose metabolism and increased body fat percentage. Pair-fed ob/ob mice exhibited even more compromised glucose metabolism and maintained strikingly similar high body fat percentage at the cost of lean body mass. Acclimatization of the microbiota to our facility took up to 5 weeks. Leptin deficiency impacted gut microbial composition, explaining 18.3% of the variance. Pair-feeding also altered several taxa, although the overall community composition at the end of the study was not significantly different. We found 24 microbial taxa associations with leptin deficiency, notably enrichment of members of Lactobacillus and depletion of Akkermansia muciniphila. Microbial metabolic functions related to energy harvest, including glycan degradation, phosphotransferase systems and ABC transporters, were enriched in the ob/ob mice. Taxa previously reported as relevant for obesity were associated with body weight, including Oscillibacter and Alistipes (both negatively correlated) and Prevotella (positively correlated). Leptin deficiency caused major changes in the mouse gut microbiota composition. Several microbial taxa were associated with body composition. Pair-fed mice maintained a pre-set high proportion of body fat despite reduced calorie intake, and exhibited more compromised glucose metabolism, with major implications for treatment options for genetically obese individuals.